Aimei Health Technology Co., Ltd. AFJK
Last close
12.06
2026-10-23
Market cap
$38.2M
2026-06-30 share count
52-week range
6.75 - 130.37
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating income | -$835.8K | -$1.1M | — |
| Pre-tax income | $1.1M | $2.6M | — |
| Income tax | $0 | $0 | $0 |
| Net income | $1.1M | $2.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Total current assets | $2.9K | $30.4K | $580.7K |
| Total assets | $12.1M | $73.8M | $70.5M |
| Total current liabilities | $3.4M | $817.0K | $24.8K |
| Total liabilities | $4.1M | $1.5M | $714.8K |
| Retained earnings | -$4.1M | -$1.5M | -$134.3K |
| Total equity | -$4.1M | -$1.5M | -$134.1K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating cash flow | -$565.1K | -$672.3K | — |
| Investing cash flow | $63.6M | -$277.7K | — |
| Financing cash flow | -$63.0M | $397.5K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-021108.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Net income | — | $2.6M | $1.1M |
Recent filings and events
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- New debt or obligation Item 2.03
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- New debt or obligation Item 2.03
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- New debt or obligation Item 2.03
- Delisting notice Item 3.01
- New debt or obligation Item 2.03
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Delisting notice Item 3.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 6770
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DMII | Drugs Made In America Acquisition II Corp. | $649.1M | — | — |
| IACO | Idea Acquisition Corp. | $437.9M | — | — |
| KRAQ | KRAKacquisition Corp | $430.8M | — | — |
| TACO | Berto Acquisition Corp. | $393.2M | 36.1x | — |
| ALDF | Aldel Financial II Inc. | $328.0M | — | — |
| ATII | Archimedes Tech SPAC Partners II Co. | $290.3M | — | — |
| FGII | FG Imperii Acquisition Corp. | $290.3M | — | — |
| SOUL | Soulpower Acquisition Corp. | $269.3M | — | — |